Announcements - OBI Pharma 台灣浩鼎

2018.Nov.23

Clarification on the news article by Up Media and other media groups

2018.Nov.21

OBI Pharma Granted FDA Orphan Drug Designation for OBI-888 for the Treatment of Pancreatic Cancer

2018.Nov.15

Department of Health (DOH) clearance of Adagloxad Simolenin (OBI-822) for a Phase III clinical study in Hong Kong

2018.Nov.12

Investigational Device Exemption (IDE) for the development of OBI-888 was approved by the US Food and Drug Administration (FDA) for its use in OBI-888 Phase I cohort expansion phase

2018.Nov.02

Clearance of Adagloxad Simolenin (OBI-822) for a Phase III clinical study in the United States

2018.Oct.29

OBI Pharma Australia Pty Ltd announces the clearance of Adogloxad Simolenin (OBI-822) for a Phase III clinical study in Australia

2018.Oct.01

OBI received notice from patent attorney’s office that product patent for OBI-822 named "Compound and Compositions of Carbohydrate Vaccine and Uses Thereof" has been approved by Taiwan Intellectual Property Office

2018.Sep.28

Taiwan FDA clearance of Adagloxad Simolenin (OBI-822) for a Phase III clinical study

2018.Sep.20

Correction on previous announcement: “Clarification on the news article by Commercial Times” to “United Daily News”

2018.Sep.20

Clarification on the news article by Commercial Times

News

Latest News

Events

Latest events